ICLIT had higher safety
redness, itching, wheezing, rash, urticaria, rhinitis, asthma, anaphylactic shock, hypotension, Systemic adverse reactions, muscular vascular edema
ADVERSE REACTIONS, ADVERSE EVENT, URTICARIA, INDURATION, RHINITIS, ASTHMA ATTACK, ASTHMA, ANAPHYLACTIC SHOCK

Adverse events associated with intra-cervical lymphatic and subcutaneous injections.Local adverse reactions mainly include redness, itching, induration, rash, etc. at the injection site. Mild local adverse reactions refer to a diameter of ≤ 4 cm, moderate local adverse reactions refer to a diameter of>4 cm and>15 minutes, both of which disappear within 24 hours. Severe local adverse reactions with a diameter of>4 cm can lead to pseudopodia, which can occur immediately or within 15 minutes; Systemic adverse reactions are divided into 5 levels: Level 1: no systemic reactions (asymptomatic), Level 2: mild systemic reactions (rhinitis, local urticaria, and mild asthma), Level 3: moderate systemic reactions (slow onset, systemic urticaria, and/or moderate asthma), Level 4: severe systemic reactions (rapid onset, systemic urticaria, muscular vascular edema, and/or severe asthma) Grade 5: anaphylactic shock (rapid onset of systemic urticaria, flushing, itching, asthma attack, wheezing, hypotension, etc.). The data of the two groups are consistent with categorical variable, and Fisher's exact test is used for data analysis and comparison.